Risk of Significant Liver Enzyme Elevation After Switching Antithyroid Drugs

Clicks: 15
ID: 321795
2026
Free PDF
Article Quality & Performance Metrics
Overall Quality
Not rated
Combines reader engagement with the AI quality analysis. This article has not been analysed, so there is no overall score — reader engagement is measured and shown alongside.
AI Quality Assessment
Not analyzed
Readership in this journal

Ranked #17 of 91 articles by views in european journal of endocrinology

Most read Least read

Bar heights use a square-root scale.

Mint this article as an NFT
Not yet minted

Create a permanent, verifiable on-chain record of this article on the Scimatic Network. The NFT is held in your Journament account, and you can withdraw it to your own wallet at any time.

5 SUSD one-off · no wallet required
Sign in to mint
Abstract
Clinically significant liver enzyme elevation is a recognized adverse effect of antithyroid drugs (ATDs) and often necessitates treatment discontinuation and switching to an alternative agent. Using TriNetX, we conducted a retrospective cohort study of patients with hyperthyroidism who initiated methimazole/carbimazole (MMI) or propylthiouracil (PTU), developed significant liver enzyme elevation within 4 months, and switched to the alternate ATD within 12 months. Baseline characteristics were indexed to the initial prescription, and outcomes were assessed for 120 days following the second prescription. The cohort included 276 patients who switched from MMI to PTU and 82 patients who switched from PTU to MMI. Significant liver enzyme elevation occurred in 111/276 (40%) and 25/82 (30%) of patients, respectively. Hepatocellular-pattern elevation occurred in 48/276 (17%) and 13/82 (16%), while cholestatic-pattern elevation occurred in 91/276 (33%) and 15/82 (18%). These findings demonstrate that significant liver injury after ATD switching is frequent but not inevitable and occurs at comparable rates across switch groups, underscoring the need for close biochemical monitoring and individualized treatment decisions.
Reference Key
openalex_W7169848676 Use this key to autocite in the manuscript while using SciMatic Manuscript Manager or Thesis Manager
Authors Rena Pollack, Joshua Stokar
Journal european journal of endocrinology
Year 2026
DOI
10.1093/ejendo/lvag123
URL
https://doi.org/10.1093/ejendo/lvag123
Keywords Keywords not found

Citations

No citations found. To add a citation, contact the admin at info@scimatic.org

Comments

No comments yet. Be the first to comment on this article.